lipoxin a4 and ticagrelor

lipoxin a4 has been researched along with ticagrelor in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Birnbaum, Y; Kodakandla, M; Ling, S; Nanhwan, MK; Nylander, S; Ye, Y	1
Birnbaum, GD; Birnbaum, I; Birnbaum, Y; Nylander, S; Ye, Y	1

Other Studies

2 other study(ies) available for lipoxin a4 and ticagrelor

Article	Year
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arteriosclerosis, thrombosis, and vascular biology, 2014, Volume: 34, Issue:9 Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Aspirin; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Enzyme Induction; Lipoxins; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Receptor, Adenosine A2A; Ticagrelor; Ticlopidine; Triazoles; Up-Regulation	2014
Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine. Cardiovascular drugs and therapy, 2016, Volume: 30, Issue:6 Topics: Adenosine; Animals; Apoptosis Regulatory Proteins; CARD Signaling Adaptor Proteins; Cardiotonic Agents; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Drug Synergism; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Interleukin-6; Lipoxins; Male; Myocardial Reperfusion Injury; Myocardium; NLR Family, Pyrin Domain-Containing 3 Protein; Obesity; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Rats, Zucker; RNA, Messenger; Rosuvastatin Calcium; Ticagrelor	2016

Article

Year

Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.

Arteriosclerosis, thrombosis, and vascular biology, 2014, Volume: 34, Issue:9

Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Aspirin; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Enzyme Induction; Lipoxins; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Receptor, Adenosine A2A; Ticagrelor; Ticlopidine; Triazoles; Up-Regulation

2014

Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine.

Cardiovascular drugs and therapy, 2016, Volume: 30, Issue:6

Topics: Adenosine; Animals; Apoptosis Regulatory Proteins; CARD Signaling Adaptor Proteins; Cardiotonic Agents; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Drug Synergism; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Interleukin-6; Lipoxins; Male; Myocardial Reperfusion Injury; Myocardium; NLR Family, Pyrin Domain-Containing 3 Protein; Obesity; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Rats, Zucker; RNA, Messenger; Rosuvastatin Calcium; Ticagrelor

2016